Germany Archives

News and Trends 25 Jun 2015

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner with Siemens to build a new production plant for personalized cancer vaccines. Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 24 Jun 2015

AYOXXA and Grünenthal collaborate on inflammation markers

AYOXXA Biosystems and Grünenthal have completed their first research collaboration to validate detection limits for a biomarker based on AYOXXA’s platform. The outcomes of this collaboration can be applied in several fields that include biological samples with very low initial volume, previously inaccessible by other immunoassays. The focus of the joint study consisted in analyzing […]

June 24, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Jun 2015

Will Boehringer Ingelheim win the race for anticoagulants?

Boehringer Ingelheim has released the last figures of its idarucizumab Phase III. The breakthrough anti-anticoagulant is being studied as an antidote to Boehringer’s blockbuster Pradaxa. Pradaxa was the first widely approved drug in a new generation of direct oral anticoagulants, a blockbuster developed by Boehringer Ingelheim. However, there is no specific antidote available yet to […]

June 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Jun 2015

Medigene plans to fund its T-cell program with €50 Millions

Munich-based Medigene is planning to raise cash through existing shareholders’ investments. The company targets up to €50M to propel its immune-oncology program with T-Cell Receptors and Dendritic Cells vaccines assets. Medigene plans a cash capital increase with subscription rights for existing shareholders by offering a new batch of shares. The company is going to present […]

June 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 Jun 2015

German Viral Vector Producer SIRION pursues its American dream and opens in Boston

The biggest biocluster of the World is still attractive. Munich-based Sirion Biotech decided to open an office to establish its US presence and benefit from Boston’s leading position in the gene therapy field. Gene Therapy is the next big thing in Biotech and is now moving from a theoretical dream to reality. Boston is clearly the hotspot for […]

June 18, 2015 - 2 minutesmins - By Philip Hemme

eye Bayer Healthcare Johns Hopkins University

News and Trends 16 Jun 2015

Bayer set a strategic alliance with J. Hopkins in retinal diseases

Bayer HealthCare and the Johns Hopkins University in Baltimore have entered into a five-year collaboration to develop ophthalmic therapies. The partners will jointly work on the discovery of treatments of retinal diseases such as age-related macular degeneration. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory […]

June 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Jun 2015

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

Genmab and its partner Jonhson&Jonhson, through its subsidiary Janssen Biotech, are trying to speed up daratumumab. The companies initiated a rolling submission for the candidate that targets multiple myeloma. The German-American partnership is trying to accelerate the arrival of daratumumab to the market, only just after the presentation of optimistic results of MOR202’s phase I/IIa. […]

June 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Jun 2015

Pieris Pharma: is it worth going to NASDAQ for only €31 Million?

Pieris Pharmaceutical is planning to raise €31M in an surprisingly low US IPO. The company seeks to advance its early-stage pipeline with a special focus on its anemia treatment, Pieris’s most advanced candidate which recently completed the enrollment of its Phase I. Pieris’ pipeline might be premature, but it is ambitious. The company’s focus includes […]

June 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

MorphoSys has presented at ASCO optimistic results of MOR202’s phase I/IIa study, a candidate treatment against multiple myeloma. The project was doubted after Celgene’s abandon, but now, safety and efficacy data have shown that there is nothing to worry about. MOR202 is a fully human monoclonal HuCAL antibody targeting CD38, a highly expressed and validated target […]

June 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

Lesson to Learn from the Best Biotech Entrepreneurs: be a Pioneer!

Last week, Biotech Entrepreneurs gathered in Berlin for the Charité Entrepreneurship Summit 2015. As a spectator, I’ll bring you the most important lessons to take on board from successful entrepreneurs. The First speaker was James Sabry, Senior VP at Genentech, which I already interviewed on the strategy of Genentech/Roche. The Californian entrepreneur, who founded the NASDAQ-listed company Cytokinetics before joining Genentech, gave […]

June 4, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 29 May 2015

Hyglos has a Solution Against Resistant Hospital Germs

Germany-based Hyglos and scientists from the universities of Tübingen, Münster and Munich join forces to develop a phage-based active substance against the dreaded hospital pathogen Staphylococcus aureus. Their secret lies in a highly effective protein from bacteria-specific viruses, the so-called bacteriophages, capable of rapidly killing the bacteria, which frequently occur in the nose. Due to the specific action of this […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 27 May 2015

Berlin’s biotech ecosystem, a fast-growing European hotspot

The Bionnale 2015, a major networking event for biotech in Berlin, is taking place today. Talks about Berlin’s cluster gave me a good insight on what’s happening here. Don’t expect Berlin to be a groundbreaking place like Boston or San Diego. The German capital has more conventional assets, but they’re definitely building a solid ecosystem. With more […]

May 27, 2015 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us